Featured at this year’s meeting on early cancer research were results from an immunotherapy Merck acquired in 2024 and ...
The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in ...
TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa® Gene TherapyREQORSA Induced Apoptosis and Decreased Tumor Volume in ALK-EML4 Positive ...
Background Sex-based differences in immune response are well established, but whether men and women derive comparable benefit ...
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight The non-small cell lung cancer clinical trial analysis report ...
April is National Cancer Prevention and Early Detection Month. According to the American Lung Association, a new statewide ...
TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease ...
MedPage Today on MSN
Early lung cancer data show why FDA approved HER2 agent in first-line
Zongertinib in phase I trial showed sustained efficacy in aggressive disease ...
Detailed price information for Nuvalent Inc Cl A (NUVL-Q) from The Globe and Mail including charting and trades.
Researchers from The University of Texas MD Anderson Cancer Center will present breakthrough studies at the American Association for Cancer Research (AACR) Annual Meeting 2026.
A 45-Year-Old Male diagnosed with Lung Cancer that had spread to his brains was successfully treated at Fortis Hospital ...
It's the deadliest cancer in the US, killing about 125,000 annually. As more fit, healthy people receive the devastating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results